• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Current opinion in investigational drugs (London, England : 2000)

    Current opinion in investigational drugs (London, England : 2000)

    JournalISSN 1472-4472eISSN 2040-3429

    年发文量

    研究主题

    论文(1676)

    排序
    1Antagonists of Bone Morphogenetic Proteins in Kidney Disease.
    Motoko Yanagita

    Bone morphogenetic proteins (BMPs) are phylogenetically conserved signaling molecules that belong to the TGFbeta superfamily and are involved in the morphogenesis, as well as the pathogenesis, of several disorders. The function of BMPs is regulated by BMP antagonists that bind directly to the proteins, thus inhibiting binding to the relevant receptors. Pharmacological doses of BMP-7 have been demonstrated to repair established renal injury and, thus, BMP antagonists modulating endogenous BMP-7 activities may be possible therapeutic targets for kidney disease. In this review, recent findings on the BMP antagonists that modify the function of BMP-7 in kidney disease are summarized, and possible implications for therapeutic strategies are discussed.

    2010
    引用
    AI阅读
    加入学术空间
    2Mutations in Melanocortin-3 Receptor Gene and Human Obesity.
    W Wang, Y-X Tao

    Growth hormone secretagogue receptor (GHSR) was originally identified as an orphan receptor in porcine and rat anterior pituitary membranes. In 1999, GHSR was deorphanized and shown to be a receptor for ghrelin, a peptide hormone secreted from the stomach. Therefore, GHSR is also called ghrelin receptor. In addition to regulating growth hormone secretion, ghrelin receptor regulates various physiological processes, including food intake and energy expenditure, glucose metabolism, cardiovascular functions, gastric acid secretion and motility, and immune function. Several human genetic studies conducted in populations originated from Europe, Africa, South America, and East Asia identified rare mutations and single nucleotide polymorphisms that might be associated with human obesity and short stature. Functional analyses of mutant GHSRs reveal multiple defects, including cell surface expression, ligand binding, and basal and stimulated signaling. With growing understanding in the functionality of naturally occurring GHSR mutations, potential therapeutic strategies including pharmacological chaperones and novel ligands could be used to correct the GHSR mutants.

    2010引用:42
    引用
    AI阅读
    加入学术空间
    3New Approaches to the Development of Adenoviral Dendritic Cell Vaccines in Melanoma.
    Lisa H. Butterfield,Lazar Vujanovic

    Considerable research in the field of immunotherapy for melanoma has demonstrated that this tumor type can be responsive to therapeutic immune activation strategies. In early clinical trials, vaccine strategies using dendritic cells (DCs) and adenovirus (Ad) vectors (AdVs) were safe and immunogenic, and induced clinical responses in a minority of patients. Research from the past several years has yielded an improved mechanistic understanding of DC biology, AdV effects on DCs and the crosstalk that occurs between antigen-loaded DCs and specific lymphocyte subsets. This knowledge base is being combined with technological advances in cytokine delivery, AdV design and in vivo DC targeting. These developments are leading to novel AdV-transduced DC-based therapeutic modalities that may further advance melanoma immunotherapy. Interactions between AdVs and DCs, initial clinical trial results, and new developments in DC engineering and in AdV biology are reviewed.

    2010引用:36
    引用
    AI阅读
    加入学术空间
    4Using NMR Approaches to Drive the Search for New CNS Therapeutics.
    David Borsook,Lino Becerra

    The use of MRI-based imaging in drug development has received increased interest recently because of the difficulties associated with the development of CNS pharmacotherapies. While not yet routine, there have been significant advances in imaging that allow this technology to be used for evaluating disease state and drug effects. For disease states, both single and longitudinal studies of non-invasive measures may be obtained to provide a read-out of disease processes and, potentially, to predict the disease state and its evolution. In addition, imaging has enabled the development of improved preclinical disease models based on changes in brain circuitry. Pharmacological MRI, the imaging-based evaluation of drug effects, includes measures of direct effects on the brain, as well as the effects of chronic dosing on brain changes and neurochemical changes associated with these brain effects using magnetic resonance spectroscopy. Thus, imaging may become an integrated process in drug development, during both the preclinical and clinical stages. However, validation, the implementation of good clinical practices and regulatory acceptance are hurdles that remain to be overcome.

    2010引用:32
    引用
    AI阅读
    加入学术空间
    5Oralair Birch, a Recombinant Major Birch Pollen Allergen Tablet for Sublingual Immunotherapy of Allergic Rhinitis Caused by Birch Pollen.
    Desiree Larenas-Linnemann

    Oralair Birch is a dissolving tablet being developed for sublingual immunotherapy (SLIT) of allergic rhinitis caused by birch pollen allergy. Oralair Birch is being developed by Stallergenes SA and Canadian licensee Paladin Labs Inc. Oralair Birch is a recombinant protein that is synthesized from the DNA coding region of Bet v 1a, the major birch pollen allergen. During preclinical characterization, Oralair Birch had comparable structural and biological properties to the natural Bet v 1 allergen. However, Oralair Birch was more homologous than the natural Bet v 1 allergen, making a greater level of quality control possible. The administration of SLIT in tablet formulation provides a more uniform dose compared with liquid drops and better local application, which might enhance local uptake into dendritic cells of the sublingual submucosa and efficacy. Using skin prick testing, the performance of recombinant Bet v 1 was comparable to the natural Bet v 1 allergen. The results of a dose-finding phase IIb/III clinical trial of Oralair Birch were positive, with the primary endpoint met by all three tested doses. A confirmatory phase III trial was planned for 2011. Oralair Birch is a very promising treatment option for patients with birch pollen allergic rhinitis.

    2010引用:35
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1676 篇论文

    高被引作者

    作者引用发文
    Mervyn Maze5522
    Michael T. Lotze4606
    Antoniu Sabina Antonela4326
    Ian Adcock3414
    Andreas Billich3406
    Noah Simeon Scheinfeld3306
    Wu-Wong J Ruth3199
    Ye Xiong3111
    Michael Chopp3111
    Asim Mahmood3111

    高产作者

    作者引用发文
    Taff Jones26211
    Sheila A. Doggrell26110
    Wu-Wong J Ruth3199
    Francis J. Dumont2449
    Norman Peter2439
    Elices M J1447
    Carlos M. Galmarini2047
    P. F. Smith2777
    Michael T. Lotze4606
    Hermann A M Mucke1536

    相关期刊

    暂无数据
    暂无数据